These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 24479980)

  • 61. Targeting integrins and adhesion molecules to combat inflammatory bowel disease.
    Marafini I; Sedda S; Pallone F; Monteleone G
    Inflamm Bowel Dis; 2014 Oct; 20(10):1885-9. PubMed ID: 25215614
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
    Dai B; Hackney JA; Ichikawa R; Nguyen A; Elstrott J; Orozco LD; Sun KH; Modrusan Z; Gogineni A; Scherl A; Gubatan J; Habtezion A; Deswal M; Somsouk M; Faubion WA; Chai A; Sharafali Z; Hassanali A; Oh YS; Tole S; McBride J; Keir ME; Yi T
    Cell Rep Med; 2021 Aug; 2(8):100381. PubMed ID: 34467254
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
    Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
    Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
    Poulakos M; Machin JD; Pauly J; Grace Y
    J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emerging biological treatments in inflammatory bowel diseases.
    van Assche G; Vermeire S; Rutgeerts P
    Minerva Gastroenterol Dietol; 2007 Sep; 53(3):249-55. PubMed ID: 17912187
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Anti-MADCAM therapy for ulcerative colitis.
    Picardo S; Panaccione R
    Expert Opin Biol Ther; 2020 Apr; 20(4):437-442. PubMed ID: 31709847
    [No Abstract]   [Full Text] [Related]  

  • 69. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis.
    Goto A; Arimura Y; Shinomura Y; Imai K; Hinoda Y
    Inflamm Bowel Dis; 2006 Aug; 12(8):758-65. PubMed ID: 16917232
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
    Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
    Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Emerging drugs in the treatment of inflammatory bowel disease: beyond anti-TNF-α].
    Kim KO; Jang BI
    Korean J Gastroenterol; 2011 Nov; 58(5):235-44. PubMed ID: 22113039
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis.
    Ha C; Kornbluth A
    Gastroenterol Hepatol (N Y); 2014 Dec; 10(12):793-800. PubMed ID: 27524947
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
    Khanna R; Mosli MH; Feagan BG
    Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
    Gerner RR; Moschen AR; Tilg H
    Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New treatment options for inflammatory bowel diseases.
    Verstockt B; Ferrante M; Vermeire S; Van Assche G
    J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.